Garheng Kong Named to LabCorp® Board of Directors Read more about Garheng Kong Named to LabCorp® Board of Directors
LabCorp Announces Proposed Sale of Senior Notes Read more about LabCorp Announces Proposed Sale of Senior Notes
LabCorp Prices $400 Million in 2.50% Senior Notes Due 2018 and $300 Million in 4.00% Senior Notes Due 2023 Read more about LabCorp Prices $400 Million in 2.50% Senior Notes Due 2018 and $300 Million in 4.00% Senior Notes Due 2023
LabCorp to Offer New FDA-Approved Companion Diagnostic for Colorectal Cancer Read more about LabCorp to Offer New FDA-Approved Companion Diagnostic for Colorectal Cancer
Laboratory Corporation of America® Holdings Announces 2013 Third Quarter Results Read more about Laboratory Corporation of America® Holdings Announces 2013 Third Quarter Results
Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 Read more about Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest Read more about LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference Read more about LabCorp is Scheduled to Present at the Morgan Stanley Global Healthcare Conference
LabCorp Applauds National Kidney Foundation’s Guidance about Testing for Chronic Kidney Disease; LabCorp’s CKD Program Provides Clinically Significant Data to Assist Diagnosis and Treatment Read more about LabCorp Applauds National Kidney Foundation’s Guidance about Testing for Chronic Kidney Disease; LabCorp’s CKD Program Provides Clinically Significant Data to Assist Diagnosis and Treatment
Laboratory Corporation of America® Holdings Announces 2013 Second Quarter Results Read more about Laboratory Corporation of America® Holdings Announces 2013 Second Quarter Results
